By doing early screening, it’s possible for researchers to accelerate process development and move to commercial bsAb ...

Ordspono is a CD20xCD3 bispecific monoclonal antibody that facilitates T cell engagement for the targeted killing of ...

Stay updated on promising new treatments for Diffuse Large B-cell Lymphoma and B-cell acute lymphoblastic leukemia in this ...

Medigene announces KRAS G12V as first target for TCR-guided T cell engagers: Planegg, Germany Tuesday, December 10, 2024, 17:00 Hrs [IST] Medigene AG, an oncology platform company ...

Hans Lee, MD, MD Anderson Cancer Center, talks about recent advancements in multiple myeloma treatment pathways.

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Financially, Immunocore has a strong cash position and stable revenue growth, but concerns remain about the pipeline's ...

Research analysts at Leerink Partnrs lifted their FY2025 earnings estimates for Zura Bio in a note issued to investors on ...

Patients with multiple myeloma are living longer, thanks to a host of new immunotherapies and targeted drugs. But there is ...

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally ...

Cantor Fitzgerald reissued their overweight rating on shares of Zura Bio (NASDAQ:ZURA – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. Several other ...